Navigation Links
Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
Date:5/12/2009

Senior Experts from Nordic Bioscience, Biomarker Strategies and Pharma on Panel

WALTHAM, Mass., May 12 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Integrating Genetic Markers in Drug Development: How Personalized Medicine is Evolving Predictive Treatment" at the BIO International Convention, being held May 18-21, 2009 in Atlanta, GA. The panel discussion will be held Tuesday, May 19 from 8-9:30 a.m. in Room B304 of the Georgia World Congress Center (Building B).

Co-presenting alongside Interleukin Genetics will be Reid Leonard, Ph.D., Executive Director of Licensing and External Research, Merck Research Laboratories; Douglas Clark, M.D., Chief Scientific Officer, Biomarker Strategies; and Morten Karsdal, Ph.D., Vice President, Research and Development, Nordic Bioscience.

"Biomarkers can be effectively used to improve the success rate in drug development. Genetic biomarkers that can be used to screen and select for patients in clinical trials to improve likelihood of trial success and improve safety for patients can save costs and reduce the time needed to bring new compounds to market," said Mr. Bender. "We're pleased that the Biotechnology Industry Organization recognizes the importance of this topic by selecting this panel to present."

The panel will provide expert insights, respectively, on integration and commercialization issues for biomarkers in drug development and how simple genetic tests and other types of biomarkers are poised to help curb an increasing innovation gap especially with regard to complex diseases. Discussion will focus on:

  • The various different biomarker types that can be used effectively for drug development
  • Genetic biomarkers, companion and triage diagnostics, and potential new applications for drug development for chronic disease
  • Biomarkers in Oncology, and future and forward looking aspects of biomarkers in drug development
  • Perspective of "Big Pharma" on use of molecular diagnostics in drug development, business models for incorporation of biomarkers, and reimbursement concerns and issues
  • A case study on biomarkers in the development of new drugs

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

About BioMarker Strategies

BioMarker Strategies, a tissue-based cancer diagnostics company located at the Johns Hopkins Science +Technology Park, is developing the SnapPath(TM) biomarker testing system to quickly test and analyze a patient's live solid tumor sample at the point of care. The company is also developing a series of pathway-based, functional, ex vivo biomarker tests to help guide an oncologist's use of targeted cancer therapeutics. The SnapPath(TM) technology is also being designed to reduce patient waiting times for molecular diagnostic test results from several weeks to several hours. For more information about BioMarker Strategies, please visit our website at www.biomarkerstrategies.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
2. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
3. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
4. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
5. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
6. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
7. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
8. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. Interleukin-12 indicates survival prospects for melanoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: